ArticleMolecular therapy. Methods & clinical development2025
Reduced rAAV interference enhances rcAAV detection sensitivity.
Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo Potency.Microorganisms · 2026Article
- An Improved Method for Determining the Infection Titer of Replication-Competent Adeno-Associated Virus.Biomedicines · 2026Article
- Overcoming inconsistent DNA extraction recovery across tissue types in qPCR assays supporting biodistribution studies.Bioanalysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Replication-competent adeno-associated virus (rcAAV) content is a crucial contaminant in the process of recombinant adeno-associated virus (rAAV) production in gene therapy products, from preclinical to clinical stages. The gold standard for qPCR-based quantification of rcAAV involves co-infecting HEK293 cells with recombinant adenovirus (rAd) and rAAV samples, followed by amplification and qPCR analysis of both the rcAAV and rAAV genomes. Here, we reported that the presence of large quantity of rAAV interferes with accurate rcAAV detection, leading to false-negative results. In addition, we present a CRISPR-based approach to improve rcAAV detection, where SpCas9 was overexpressed in HEK293 cells and single-guide RNA (sgRNA) was delivered via rAd5 to cleave the rAAV genome. The assay detected as few as 3E2 vector genomes (vg) of rcAAV, whereas the traditional method using the same sample batch failed to detect such low levels. This study not only expands our knowledge of adeno-associated virus (AAV) biology but also highlights a CRISPR-based assay that improves the sensitivity of rcAAV detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.